Eli Lilly and Company, Bracknell, UK.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
Diabetes Obes Metab. 2022 Sep;24(9):1861-1868. doi: 10.1111/dom.14775. Epub 2022 Jun 13.
To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes.
The primary analysis was a Bucher aITC of the change from baseline at week 40 in HbA1c (%) and body weight (kg). Aggregate data from the SURPASS-2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE metformin-only treated patients were used for primary analysis.
The SURPASS-2 refined population comprised 238/245/240 and 240 participants for tirzepatide 5/10/15 mg and semaglutide 1 mg, respectively. The SUSTAIN FORTE metformin-only population comprised 222 and 227 participants for semaglutide 1 and 2 mg, respectively. In this aITC, tirzepatide 10 and 15 mg significantly reduced HbA1c versus semaglutide 2 mg with an estimated treatment difference (ETD) of -0.36% (95% confidence interval [CI] -0.63, -0.09) and -0.4% (95% CI -0.67, -0.13), respectively. Tirzepatide 10 and 15 mg significantly reduced body weight versus semaglutide 2 mg with an ETD of -3.15 kg (95% CI -4.84, -1.46) and -5.15 kg (95% CI -6.85, -3.45), respectively. There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg on change from baseline in HbA1c and body weight.
In this aITC, HbA1c and weight reductions were significantly greater for tirzepatide 10 and 15 mg versus semaglutide 2 mg and were similar for tirzepatide 5 mg versus semaglutide 2 mg. These findings provide comparative effectiveness insights in the absence of a head-to-head clinical trial.
对替尔泊肽 5/10/15mg 与司美格鲁肽 2mg 治疗 2 型糖尿病患者的疗效进行调整后的间接治疗比较（aITC）。
主要分析是在第 40 周时，HbA1c（%）和体重（kg）的基线变化的 Bucher aITC。使用符合 SUSTAIN FORTE 研究的 HbA1c 纳入标准的 SURPASS-2 研究的汇总数据和 SUSTAIN FORTE 二甲双胍单药治疗患者的数据进行主要分析。
SURPASS-2 精制人群分别为替尔泊肽 5/10/15mg 和司美格鲁肽 1mg 组的 238/245/240 和 240 名参与者，SUSTAIN FORTE 二甲双胍单药人群分别为司美格鲁肽 1 和 2mg 组的 222 和 227 名参与者。在这项 aITC 中，替尔泊肽 10 和 15mg 与司美格鲁肽 2mg 相比，显著降低 HbA1c，估计治疗差异（ETD）分别为-0.36%（95%置信区间[CI] -0.63，-0.09）和-0.4%（95% CI -0.67，-0.13）。替尔泊肽 10 和 15mg 与司美格鲁肽 2mg 相比，显著降低体重，ETD 分别为-3.15kg（95% CI -4.84，-1.46）和-5.15kg（95% CI -6.85，-3.45）。替尔泊肽 5mg 与司美格鲁肽 2mg 相比，HbA1c 和体重的基线变化无显著差异。
在这项 aITC 中，替尔泊肽 10 和 15mg 与司美格鲁肽 2mg 相比，HbA1c 和体重的降低更为显著，而替尔泊肽 5mg 与司美格鲁肽 2mg 相比则相似。这些发现提供了在没有头对头临床试验的情况下的比较有效性见解。
